Medifast (NYSE:MED) Announces Earnings Results, Beats Estimates By $0.36 EPS

Medifast (NYSE:MED) announced its earnings results on Monday. The specialty retailer reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.36, FiscalAI reports. Medifast had a negative net margin of 4.84% and a negative return on equity of 4.27%. The business had revenue of $76.04 million for the quarter, compared to analyst estimates of $69.20 million. Medifast updated its FY 2026 guidance to -2.750–1.550 EPS and its Q2 2026 guidance to -1.000–0.500 EPS.

Here are the key takeaways from Medifast’s conference call:

• Coach productivity rose meaningfully, up ~19% year?over?year and 16% sequentially, driven by more clients per coach and stronger referral activity — management framed this as an early leading indicator of future growth.
• Active earning coaches fell ~44.9% year?over?year to ~14,000, contributing to a 34.3% decline in Q1 revenue to $76.0M and a net loss of $2.1M, underscoring near?term top?line pressure.
• The company has completed a strategic repositioning toward “metabolic health” anchored by its Metabolic Synchronization science (e.g., 14% visceral fat reduction and 98% lean mass retention in 16 weeks) and plans a new proprietary metabolic product system to be launched to coaches later in 2026.
• Management expects >$30M in cost savings from a realigned cost structure, reconfirmed full?year 2026 guidance ($270M–$300M revenue) and said improvements toward re?attaining profitability should begin in Q4 2026 and continue into 2027.
• Financial position is solid with ~$169M in cash and investments, no debt and healthy working capital, but near?term guidance remains wide (Q2 $60M–$80M) and company still expects quarterly losses before the planned Q4 inflection.

Medifast Stock Down 3.0%

Medifast stock traded down $0.33 on Monday, hitting $10.58. The company’s stock had a trading volume of 150,459 shares, compared to its average volume of 241,674. The firm has a market cap of $116.76 million, a P/E ratio of -6.19 and a beta of 0.55. The company has a fifty day moving average price of $10.41 and a 200-day moving average price of $11.10. Medifast has a one year low of $9.22 and a one year high of $15.46.

Insider Transactions at Medifast

In other Medifast news, CEO Daniel R. Chard purchased 17,678 shares of the stock in a transaction on Friday, March 20th. The shares were purchased at an average price of $10.11 per share, with a total value of $178,724.58. Following the acquisition, the chief executive officer directly owned 17,678 shares of the company’s stock, valued at $178,724.58. This represents a ? increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 3.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medifast

Several institutional investors and hedge funds have recently bought and sold shares of MED. BNP Paribas Financial Markets increased its holdings in Medifast by 103.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock valued at $32,000 after buying an additional 1,187 shares during the period. Quantbot Technologies LP bought a new stake in Medifast in the 3rd quarter valued at $37,000. Intesa Sanpaolo Wealth Management bought a new stake in Medifast in the 4th quarter valued at $47,000. State of Wyoming bought a new stake in Medifast in the 4th quarter valued at $59,000. Finally, Strs Ohio bought a new stake in Medifast in the 1st quarter valued at $78,000. Institutional investors own 95.51% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on MED. Stephens dropped their target price on shares of Medifast from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 19th. Wall Street Zen raised shares of Medifast from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Medifast in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Medifast has an average rating of “Reduce” and an average target price of $12.00.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight?loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight?management solutions.